Background We aimed to compare overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the addition of cetuximab to concurrent chemoradiation for patients with inoperable stage III non-small-cell lung cancer.
Introduction
The commonly accepted radiation therapy dose (60-63 Gy in 1·8-2·0 Gy fraction sizes) for patients with stage III non-small-cell lung cancer was established by the Radiation Therapy Oncology Group (RTOG) 7301 trial and has remained unchanged for more than 30 years. 1 With the idea that increasing radiation dose would improve both local-regional control and overall survival, the RTOG and other investigators did separate prospective phase 1 and 2 trials to establish the safety and effi cacy of increasing the total radiation dose in the setting of concurrent chemotherapy while reducing irradiated volumes by use of image guidance and either three-dimensional conformal or intensity-modulated radiation therapy for locally advanced non-small-cell lung cancer. [2] [3] [4] [5] [6] [7] Findings from these trials were similar, showing that a maximum tumour dose of 74 Gy given with concurrent weekly paclitaxel and carboplatin was safe and resulted in a median overall survival of roughly 24 months [3] [4] [5] [6] versus a median overall survival of around 17·1 months in patients given a 60 Gy dose in RTOG 9410. 8 Our trial (RTOG 0617) was designed to establish whether a 74 Gy dose was better than a 60 Gy dose and whether adding cetuximab to concurrent chemoradiation would confer an overall survival benefi t. Cetuximab is a chimerised antibody of the immunoglobulin G1 subclass that blocks binding of EGF and TGF α to EGFR. 9 The use of cetuximab in this setting was tested in RTOG 0324, a phase 2 study combining chemoradiation with cetuximab in patients with unresectable stage III non-small-cell lung cancer. 10 The trial enrolled 93 patients, showed a median survival of 22·7 months, and 24-month overall survival of 49·3%. On the basis of these encouraging data, we investigated cetuximab in this trial.
Methods

Study design and participants
In this randomised phase 3 study, we recruited patients aged 18 years and older with stage IIIA/IIIB non-small cell-lung cancer from 185 institutions in the USA and Canada. Eligibility criteria included having stage IIIA or IIIB non-small-cell lung cancer, no previous invasive cancer during the previous 3 years, Zubrod performance status score of 0-1, less than 10% weight loss (in the month before study entry), and pulmonary function (before or after broncho dilation) of 1·2 L per s or higher. Tumour histology was classifi ed as squamous cell, adenocarcinoma, large-cell carcinoma, or non-small-cell lung cancer not otherwise specifi ed. Specifi c mutational analyses were not necessary for trial entry. Patients with contralateral hilar or supraclavicular adenopathy or Pancoast tumours were excluded because of the risk of lung or brachial plexus toxic eff ects. Minimum pleural eff usions were allowed if they were transudative and cytologically negative by thoracentesis. CT of the lung and upper abdomen and brain MRI with contrast was needed within 6 weeks of registration. Laboratory investigation requirements included the following: absolute neutrophil count of 1800 cells per μL or higher, platelets 100 000 cells per μL or higher, haemoglobin 10 g/dL or higher, normal serum creatinine and bilirubin, and aspartate amino transferase and alanine aminotransferase concen trations 2·5 times or lower the upper institutional normal limit.
The institutional review board of each participating institution approved the study protocol. All patients were required to read and sign an institutional review board approved informed consent document.
Randomisation and masking
We randomly assigned (1:1:1:1) eligible patients to one of four treatment groups: 60 Gy versus 74 Gy with concurrent and consolidation chemotherapy, with or without cetuximab. Treatment groups were assigned with the permuted block randomisation scheme described by Zelen 11 and stratifi ed by radiotherapy technique (three dimensional conformal radiotherapy vs intensity-modulated radiation therapy), Zubrod performance status at the time of enrollment (0 vs 1), use of PET during tumour staging (no vs yes), and histology (squamous vs non-squamous). Allocation sequences were generated algorithmically at the RTOG statistics and data management centre, and access to these sequences by participating centres and statistics and data management was prohibited. Participating centres enrolled patients initially via the RTOG website, and then beginning on June 2, 2011, via the National Cancer Institute's Oncology Patient Enrollment Network (OPEN) enrolment system, which remotely accessed the allocation sequence as necessary through a secure connection. Treatment group assignments, once allocated, were not masked.
Procedures
Radiation therapy was given 5 days per week (ie, Monday to Friday with the weekend off ) in 2 Gy fractions daily by use of 6-18 MV x-rays. Use of image-guided radiation therapy was encouraged. Both three-dimensional conformal and intensity-modulated radiation therapy were allowed. Compliance with normal tissue dose constraints was encouraged but not neccessary (appendix p 1). Radiation doses were prescribed to the planning target volume. Motion management was required, and internal target volumes, clinical target volumes, and planning target volumes depended on which motion management method was used. Use of PET or CT and four-dimensional CT for radiation therapy planning was encouraged. Elective nodal irradiation was not permitted. The gross tumour volume was defi ned as the primary tumour and any regionally involved nodes on CT (>1 cm on short axis) or pretreatment PET scan (standardised uptake value >3). The internal target volume was defi ned as the envelope that encompasses the gross tumour volume plus ventilatory motion. Clinical target volume margins were 0·5-1·0 cm beyond the internal target volume. Planning target volume margins were 0·5-1·5 cm beyond the clinical target volume, depending on the use of four-dimensional CT for planning and image-guided radiation therapy for delivery. The appendix shows institutional credentialing protocol compliance defi nitions for both radiation therapy and chemotherapy (appendix p 2). Radiation therapy plans were reviewed centrally and scored for both target delineation and dose and normal tissue delineation and dose on submitted plans. Per-protocol planning target volume coverage was achieved when more than 99% of the planning target volume received 93% or more of the prescribed dose and when minimum margin values for both clinical target volume and planning target volume were achieved. Chemotherapy consisted of weekly paclitaxel (45 mg/m² per week) and carboplatin (area under the curve [AUC] 2 per week) during radiation therapy. 2 weeks after chemoradiation, two cycles of consolidation chemotherapy separated by 3 weeks were given consisting of paclitaxel (200 mg/m²) and carboplatin (AUC 6). Paclitaxel was given for 3 h 30 min after diphenhydramine (25-50 mg), followed by an H2 blocker, and dexamethasone (oral or intravenous administration allowed). Carboplatin was given for 30 min with standard anti-emetics after paclitaxel.
Patients in the cetuximab groups received the agent during both concurrent and consolidative phases. Cetuximab was given at 400 mg/m² intravenously on day 1, with concurrent chemoradiation starting on day 8. Weekly cetuximab dosing was 250 mg/m², given before chemotherapy and radiation therapy that day. Consolidation cetuximab (250 mg/m² per week) was given weekly during consolidation.
We did follow-up assessments every 3 months for the fi rst year, every 4 months for year 2, every 6 months for years 3-5, then every year. Routine follow-up assessments included assessment of vital signs, Zubrod performance status, and any adverse events. CT scans were done every 6 months for the fi rst 2 years, and then once a year. Pulmonary functioning was assessed at 6 months and then 1 year after completion of treatment. All data were collected by the enrolling site and then reported to RTOG via standard case report forms. All adverse events were graded with the CTCAE version 3.0 criteria; response was assessed per the RECIST criteria. 12 Pathological biomarker analysis was based on the FLEX trial, 13 which suggested that the use of cetuximab in patients with EGFR expressing non-small-cell lung cancer conferred a survival benefi t. We assessed the association between EGFR status in tumour samples that were available and the eff ect of cetuximab on patient outcomes. EGFR status established centrally was reported as H scores on the basis of EGFR immunohistochemical staining, with a score of 200 or more defi ned as a positive score.
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Outcomes
The coprimary objectives of this trial were to compare the overall survival of patients given 74 Gy with those given 60 Gy conformal radiation therapy with concurrent chemotherapy and to compare the overall survival of patients given cetuximab with those not given cetuximab. There were several secondary objectives including a comparison of progression-free survival and local regional tumour control, comparison of toxic eff ects between 74 Gy versus 60 Gy, and between cetuximab versus without cetuximab, to assess patientreported quality of life in each group of the trial (Movsas et al, unpublished data), and to explore biological markers that might predict clinical outcome (ie, EGFR expression by use of H score).
Statistical analysis
The trial was a two-by-two factorial design, with radiation therapy dose as one treatment factor and cetuximab as the other. A log-rank test for each factor at one-sided α of 0·0125 (α of 0·0250 for both factors to account for multiple comparisons) would yield statistical power of 80% to detect an improvement in median overall survival from 17·1 months to 24 months after 339 deaths were reported from a sample of 500 patients. Three interim analyses with early stopping criteria with Haybittle 14 and Peto 15 boundaries for effi cacy and Freidlin and Korn 16 methods for futility were planned after 85, 170, and 225 events, and overseen by the independent RTOG data monitoring committee.
Results are reported on a modifi ed intent-to-treat basis with all patients included in the assigned group, irrespective of treatment received, but excluding those patients who were found not to meet the pre-defi ned eligibility criteria. Endpoints of overall survival, progression-free survival, local failure, and distant metastasis were measured from the date of randomisation. We estimated overall survival and progression-free survival with the Kaplan-Meier method, 17 compared with the log-rank test, 18 and modelled with the Cox proportional hazards method. 19 We used the cumulative incidence method 20 to estimate local failure and distant metastasis rates, which were compared with the Gray's test, 21 and that were modelled with the Fine-Gray method. 22 We compared categorical data with χ² test statistics; continuous data were compared with t tests or Wilcoxon rank sum tests as appropriate. All analyses were done with SAS version 9.2 except for Fine-Gray modelling, which was done with R (version 2.11.1). The appendix shows additional methods (appendix p 8).
At the fi rst interim analysis in June, 2011, the monitoring committee established that the trial had crossed the futility boundary with respect to high-dose radiation. The high-dose radiation groups were then closed, and the trial continued accruing patients to the 60 Gy with and without cetuximab groups. At the third interim analysis in June, 2013, it was likewise established that a futility boundary with respect to cetuximab had been crossed. The study is registered with ClinicalTrials.gov, number NCT00533949.
Role of the funding source
The trial design, data collection, analysis, interpretation of the data, and writing of the report was the responsibility of the authors. The NCI approved the trial design, monitored trial progress, and received the two interim futility analyses of both the radiotherapy and cetuximab endpoints. Bristol-Myers Squibb agreed to the initial trial design and received the data reports for both the radiotherapy and cetuximab endpoints. RTOG statisticians (RP and CH) had access to the raw data. The corresponding author had full access to all of the data and the fi nal responsibility to submit for publication.
Results
Between Nov 27, 2007, and Nov 22, 2011, the trial accrued 544 patients from 185 institutions (hospital and outpatient centres; median two per institution, range 1-18), 464 while the radiotherapy dose randomisation was still in eff ect, and 514 while the cetuximab randomisation was in eff ect. The radiotherapy randomisation was closed early because of futility, but the cetuximab randomisation met targeted accrual goals. This report includes all data reported as of Oct 24, 2013; median follow-up was 21·2 months (IQR 10·5-30·3). Figure 1 shows the trial profi le. After exclusions, 495 patients were available for analysis (424 for the radiation therapy endpoint and 465 for the cetuximab endpoint). Table 1 shows patient characteristics. The median age was 64 years (IQR 57-70), and most patients were white men. Treatment technique was equally distributed between three-dimensional conformal radiation therapy and intensity-modulated radiation therapy. 449 (91%) patients underwent diagnostic PET staging.
Protocol compliance reviews were done for both radiation therapy and for systemic treatment (appendix pp 3-7). Rates of protocol non-compliance The trial was initially opened only to the radiation dose groups. After the initial 30 patients were enrolled, the cetuximab groups were opened to accrual. After the 464th patient was enrolled, the 74 Gy and 74 Gy plus cetuximab groups were closed to accrual because the futility boundary relating to the radiation therapy endpoint had been crossed. We then continued to enrol to the 60 Gy and 60 Gy plus cetuximab groups. Thus the numbers of patients enrolled to the radiation therapy and cetuximab endpoints diff er according to these three enrolment periods. CBC=complete blood count.
with radiation therapy were greater in the high-dose group than in the standard-dose group Median follow-up for the 419 analysable patients randomly assigned to the radiation therapy dose question was 22·9 months (IQR 27·5-33·3). Table 2 shows overall survival, progression-free survival, and failure rates. Median overall survival for the standarddose group was 28·7 months (95% CI 24·1-36·9) and that for the high-dose group was 20·3 months (95% CI 17·7-25·0; one-sided p=0·996 for superiority of 74 Gy; two-sided p=0·008). The hazard ratio for radiation dose (74 Gy vs 60 Gy) on overall survival was 1·38 (95% CI 1·09-1·76; fi gure 2). 116 (58%) of 217 patients were alive at 2 years in the standard-dose group compared with 87 (45%) of 207 patients in the high-dose group. Oesophageal doses were signifi cantly higher in the highdose group. Heart dose was also signifi cantly higher in the high-dose group. The appendix shows a complete summary of dosimetric variables (appendix p 9-10). On univariate analysis, increasing values of gross tumour volume, planning target volume, lung V5, heart V5, and heart V30 were associated with increased risk of death. On multivariate analyses, factors predicting overall survival were radiation dose (60 Gy), maximum oesophagitis grade, planning target volume, and heart V5 and V30. Notably, neither radiotherapy compliance nor technique (three-dimensional conformal radiation therapy or intensity-modulated radiation therapy) were signifi cant in these analyses. The appendix shows the multivariate analyses for both the radiation therapy and cetuximab endpoints (appendix pp 10-11).
To assess whether radiation therapy quality compromised overall survival or local failure within the trial, we did separate analyses limiting the dataset to cases compliant on two measures-physician radiation therapy review and 95% of the dose covering 90% or more of the planning target volume. Signifi cant overall survival benefi ts were maintained for the 60 Gy group (appendix p 12). Although this unplanned subset analysis excludes patients who did not complete the radiation therapy course, it strongly suggests that radiation therapy compliance was not the cause for the poorer performance of the high-dose group.
Additionally, we assessed the interaction of radiation therapy dose and cetuximab use to establish whether the use of cetuximab aff ected the dose results. We recorded no interactive eff ect (p interaction =0·3984; appendix p 13).
Median follow-up for the 465 analysable patients randomly assigned to the cetuximab question was 21·3 months (IQR 23·5-29·8). We did a separate planned retrospective analysis of the association of EGFR expression and outcome with cetuximab by use of prospectively obtained specimen. There were 203 patients (101 given cetuximab and 102 not given cetuximab) with usable samples (table 1 ). An EGFR H-score less than 200 (low EGFR expression) was noted more commonly in patients with nonsquamous histology whereas an EGFR H score of 200 or more (EGFR-overexpression) was more common in those with squamous histology (p=0·0003). We noted no diff erences in outcomes between H-score groups. Table 3 continues on next page)
Adverse events were graded with CTCAE version 3.0. Acute adverse events are those arising within 90 days of completion of all protocol treatment. Late adverse events are those arising after 90 days of completion of all protocol treatment. Limited to acute adverse events arising in at least 10% of patients and late adverse events arising in at least 5% of patients. Table 3 : Most frequently reported adverse events by term, defi nitely, probably, or possibly related to protocol treatment 42·0 months (95% CI 20·6-not reached) versus 21·2 months (17·2-29·2) for the no-cetuximab group (HR 1·72, 95% CI 1·04-2·84; two-sided log-rank p=0·032, statistical power=0·4; fi gure 3).
We noted no diff erence in severe (grade ≥3) toxic eff ects between the radiation therapy dose groups (165 [76%] of 217 patients in the standard-dose group and 163 [79%] of 207 in the high-dose group); by contrast, 205 (86%) of 237 patients in the cetuximab group had severe toxic eff ects versus 160 (70%) of 228 in the nocetuximab group (p<0·0001; appendix p 14-26). Notably, eight treatment-related deaths arose in the high-dose group versus three in the standard-dose group, and ten patients in the cetuximab group died because of treatment-related deaths versus fi ve deaths in the nocetuximab group (appendix p 27). The overall number of patients with grade 3 or worse pulmonary events was 44 (20%) of 217 in the standard-dose group versus 39 (19%) of 207 in the high-dose group (p=0·71). Rates of grade 3 or higher radiation pneumonitis were similar between groups, arising in 15 (7%) of 217 patients in the standard-dose and nine (4%) of 207 patients in the (4%)
Adverse events were graded with CTCAE version 3.0. Acute adverse events are those arising within 90 days of completion of all protocol treatment. Late adverse events are those arising after 90 days of completion of all protocol treatment. Limited to acute adverse events arising in at least 10% of patients and late adverse events arising in at least 5% of patients. 
Discussion
We noted two major fi ndings in this study: increasing radiation therapy dose to 74 Gy with 2 Gy per fraction did not improve overall survival and might be potentially harmful, and the addition of concurrent cetuximab, an anti-EGFR antibody, did not improve overall survival. However, use of standard-dose (60 Gy) radiation therapy with concurrent weekly carboplatin and paclitaxel, followed by consolidation chemotherapy with these drugs, resulted in a median overall survival of 28·7 months and 116 (58%) of 217 patients alive at 2 years. These results were better than anticipated and set a new benchmark for patients with inoperable stage III non-small-cell lung cancer given chemoradiation (panel). Notably, this is the fi rst RTOG phase 3 trial that incorporated diagnostic PET for disease staging. Staging PET or PET/CT scans were obtained for most patients in both groups. Thus, stage migration might contribute to the reason the 60 Gy group did better than anticipated.
Findings of trials leading to the development of RTOG 0617 implied a survival benefi t from 74 Gy, but this benefi t was not realised in this study. In fact, the overall survival interval after 74 Gy was worse than that after 60 Gy (20·3 months vs 28·7 months; one-sided p=0·004).The poorer results with 74 Gy are probably caused by a combination of factors. Treatment-related deaths were more common in the high-dose group than in the low-dose group. Concurrent chemotherapy was more diffi cult to complete in the high-dose group than in the low-dose group. Radiation therapy planning was more likely to be non-compliant in the high-dose group, and planning target volume coverage by the 95% isodose line was poorer in the high-dose group. Concerns that non-compliance to radiation therapy in the high-dose groups would produce these results led us to analyse overall survival only in those patients with plans compliant with the protocol; nevertheless, overall survival was still better in the standard-dose groups than in the high-dose groups, suggesting that the radiotherapy dose results are attributable to other factors rather than radiation therapy compliance.
Of factors included in multivariate analyses, heart dose might best explain why patients given 74 Gy did worse than patients given the 60 Gy dose. The trial protocol suggested dose-volume guidelines for the heart, but did not need compliance. Thus, when trying to limit normal lung exposure during treatment planning, the heart volume was likely to receive generous doses of radiation therapy in both groups. Multivariate models generated with heart V5 (the percentage of heart volume receiving ≥5 Gy) and V30, on separate multivariate analysis, are both important predictors of patient survival. We chose heart V5 because of its varied distribution across all cases, and heart V30 because it is more meaningful in clinical applications and is not overly informed with the planned dose assignment. Although we were not able to track specifi c heart toxicity outcomes in this trial, the the fi ndings of heart V5 and heart V30 being predictors of patient death is a major contribution to the specialty
Panel: Research in context
Systematic review
We did a thorough systematic review of radiation dose escalation and the use of cetuximab in patients with locally advanced non-small-cell lung cancer before we designed this trial. We searched Medline and PubMed between Jan 1, 1980, and Jan 1, 2006, with the search terms "radiation dose", "radiation dose escalation", "lung cancer", "prospective trials", "cetuximab", "anti-EGFR", "systemic therapy", and "chemotherapy" for publications in English. We identifi ed relevant prospective trials testing radiation dose escalation or the use of anti-EGFR antibody therapy, which formed the basis for this study.
Interpretation
This phase 3 trial was the result of phase 1 and 2 trials that were undertaken and reported from RTOG 0117, CALGB 30105, NCCTG N0628, and institutional studies from the University of North Carolina, NC, USA. These data suggested that a dose of 74 Gy in 2 Gy daily fractions was tolerable and achieved a projected median survival of 24 months in patients with locally advanced non-small-cell lung cancer. However, the results of this work did not translate into a benefi t for radiation dose escalation. Our fi ndings show that when 2 Gy daily fractions of radiation therapy are used, 74 Gy is not better and might be worse than 60 Gy; nevertheless, our fi ndings set a new benchmark for median overall survival in patients with locally advanced non-smallcell lung cancer and should be used to design future trials. 60 Gy with 2 Gy daily fractions remains the standard of care in this setting. The use of cetuximab did not result in improvements in overall survival, and strict heart dose constraints will be used in future NRG Oncology trials. NRG Oncology is continuing to pursue radiotherapy dose intensifi cation in clinical trials in progress. RTOG 1106 is using a mid-treatment PET adapted hypofractionated radiation therapy boost to intensify radiation dose to residual tumour volumes during a total duration of 30 fractions (NCT01507428). RTOG 1308 is a phase 3 trial exploiting the potential of protons compared with photons to escalate radiation dose to 70 Gy while applying strict dose volume constraints to adjacent normal tissues (NCT01993810). Both of these trial designs were built on the knowledge gained from RTOG 0617.
of radiation oncology. We noted variability in heart contouring within the submitted plans (appendix p 4). A secondary analysis is planned to analyse heart dosevolume eff ects on overall survival by use of recontoured heart structures (pericardium, atria, and ventricles). Future lung cancer trials through NRG Oncology (formerly RTOG) will include heart dose-volume limitations. Other issues that might have aff ected the trial's outcome include the greater number of deaths in the high-dose groups, the extended duration of radiation therapy to 7·5 weeks, and uncertainty about the true cause of death. Cause of death was reported to RTOG by the local investigator and was probably taken from the death certifi cate, creating uncertainty about cancer progression or heart-related toxicity events.
Data leading to the incorporation of cetuximab into RTOG 0617 were from a phase 3 study 23 of squamous cell cancer of the head and neck and from a single-arm phase 2 study of stage III non-small-cell lung cancer within the RTOG. Bonner and colleagues 23 had shown benefi ts in both locoregional control and overall survival when cetuximab was added to radiation for locally advanced head and neck cancer. Blumenschein and colleagues 10 had noted that adding cetuximab to concurrent chemoradiation for patients with nonsmall-cell lung cancer led to a median overall survival of 22·7 months. However, the use of cetuximab had no meaningful eff ect on overall survival in our trial. Patients entered in the trial were not selected on the basis of EGFR status. Thus, most patients in this trial probably did not have EGFR mutations or have amplifi ed EGFR expression. To explore the association between EGFR expression and outcomes with cetuximab, we determined the EGFR H score in the subpopulation of patients with enough pathological material for central review. This was a planned retrospective analysis of prospectively collected pathological specimens. Interpretation of H-score analysis was limited because only about half the patients in the cetuximab analysis had available tissue samples. Nevertheless, the data suggest that patients with an H score of 200 or more might benefi t from the addition of cetuximab to chemoradiation but that cetuximab might be detrimental for patients with an H score of less than 200. These data should not change practice, but they are worthy of further exploration in subsequent trials. No additional mutational analyses are planned as part of RTOG 0617 because of limited residual pathological material.
In conclusion, in this trial of patients receiving chemoradiation for stage III non-small cell lung cancer, 74 Gy delivered in 2 Gy daily fractions was not better than 60 Gy and might be potentially harmful. Cetuximab provided no benefi t in terms of overall survival. The standard radiation dose with concurrent chemotherapy for patients with inoperable stage III non-small-cell lung cancer should remain 60 Gy.
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